Published in PLoS Med on November 15, 2011
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med (2016) 3.71
Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment. Lancet Glob Health (2015) 2.92
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19
Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr (2013) 2.13
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis (2012) 1.97
HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep (2012) 1.83
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (2013) 1.55
Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr (2012) 1.44
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med (2012) 1.35
Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med (2013) 1.28
Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc (2015) 1.14
Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS (2012) 1.13
Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr (2013) 1.12
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One (2012) 1.12
Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. J Acquir Immune Defic Syndr (2013) 1.11
HIV treatment as prevention: issues in economic evaluation. PLoS Med (2012) 1.10
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLoS Med (2016) 1.10
Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc (2015) 1.09
HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med (2012) 1.08
An action agenda for HIV and sex workers. Lancet (2014) 1.06
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med (2014) 1.03
Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS One (2014) 1.02
The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance. Cost Eff Resour Alloc (2013) 1.02
Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther (2012) 1.02
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS (2016) 0.99
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One (2014) 0.97
Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire. J Infect Dis (2013) 0.95
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J (2016) 0.94
How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One (2013) 0.92
Antiretroviral medication and HIV prevention: new steps forward and new questions. Ann Intern Med (2012) 0.85
Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. AIDS Behav (2015) 0.83
Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2016) 0.83
ARV-based HIV prevention for women - where we are in 2014. J Int AIDS Soc (2014) 0.82
Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role. J Acquir Immune Defic Syndr (2015) 0.82
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS (2015) 0.82
Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS One (2013) 0.81
Individual-based simulation models of HIV transmission: reporting quality and recommendations. PLoS One (2013) 0.81
HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc (2014) 0.81
HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment. Med Decis Making (2015) 0.81
Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One (2014) 0.80
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med (2015) 0.80
Effectiveness of ART and condom use for prevention of sexual HIV transmission in serodiscordant couples: a systematic review and meta-analysis. PLoS One (2014) 0.80
Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One (2015) 0.79
Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm (2012) 0.79
Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda. BMC Infect Dis (2017) 0.78
HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav (2015) 0.78
PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials. J Acquir Immune Defic Syndr (2016) 0.78
Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis (2016) 0.77
Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk? Contraception (2016) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Risk Factor Associated with Negative Spouse HIV Seroconversion among Sero-Different Couples: A Nested Case-Control Retrospective Survey Study in 30 Counties in Rural China. PLoS One (2016) 0.75
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS One (2016) 0.75
Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence. PLoS One (2016) 0.75
Scale up use of family planning services to prevent maternal transmission of HIV among discordant couples: a cross-sectional study within a resource-limited setting. Patient Prefer Adherence (2016) 0.75
Infection in 2012: mixed results of pre-exposure prophylaxis for HIV prevention. Nat Rev Urol (2013) 0.75
Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infect Dis (2016) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS (2003) 8.05
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 7.72
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet (2008) 5.93
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS (2007) 4.74
A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis (2001) 4.73
Public health. Global HIV/AIDS policy in transition. Science (2010) 4.62
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS (2011) 3.35
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
The condom is an 'intruder' in marriage: evidence from rural Malawi. Soc Sci Med (2007) 2.68
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A (2010) 2.25
A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making (2002) 2.12
Pre-exposure prophylaxis for HIV infection: what if it works? Lancet (2007) 2.07
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect (2012) 1.81
HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog (2010) 1.69
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Preventing HIV transmission with antiretrovirals. Bull World Health Organ (2009) 1.50
Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet (2010) 1.46
Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res (2010) 1.42
An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect (2002) 1.40
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis (2009) 1.03
Ethical allocation of preexposure HIV prophylaxis. JAMA (2011) 0.99
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet (2002) 7.64
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
HIV decline associated with behavior change in eastern Zimbabwe. Science (2006) 6.98
Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate. Am J Bioeth (2011) 6.69
Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract (2011) 6.24
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet (2011) 5.58
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 4.49
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis (2007) 4.12
Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol (2004) 4.03
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Host immunity and synchronized epidemics of syphilis across the United States. Nature (2005) 3.34
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat (2005) 3.23
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
High HIV prevalence among men who have sex with men in Soweto, South Africa: results from the Soweto Men's Study. AIDS Behav (2009) 3.06
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
HIV, syphilis and heterosexual bridging among Peruvian men who have sex with men. AIDS (2002) 3.03
Effects of unconditional and conditional cash transfers on child health and development in Zimbabwe: a cluster-randomised trial. Lancet (2013) 2.98
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS (2009) 2.97
HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res (2007) 2.78
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr (2007) 2.71
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. AIDS (2006) 2.67
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low- and middle-income countries. Int J Epidemiol (2010) 2.59
Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med (2007) 2.56
Initial burden of disease estimates for South Africa, 2000. S Afr Med J (2003) 2.56
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis (2006) 2.43
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol (2011) 2.41
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS (2006) 2.34
Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS (2007) 2.23
Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis (2010) 2.23
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21